Massachusetts General Hospital

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Massachusetts General Hospital

  Boston, Massachusetts 02214

  1,215 trials

• Massachusetts General Hospital

  Charlestown, Massachusetts 02129

  29 trials

• Massachusetts General Hospital - Boston

  Boston, Massachusetts 02114

  4 trials

• Massachusetts General Hospital (Data Collection Only)

  Boston, Massachusetts 02114

  4 trials

• Massachusetts General Hospital (Site 0003)

  Boston, Massachusetts 02114

  4 trials

• Mass General

  Boston, Massachusetts 02114

  4 trials

• Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)

  Boston, Massachusetts 02114

  3 trials

  • NCT07733765A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  • NCT04006457Long-Term PF-06651600 for the Treatment of Alopecia Areata

  • NCT03422822Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

• Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases

  Boston, Massachusetts 02114

  3 trials

  • NCT07108387Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

    Contact: Joseph Sadok

  • NCT05306873Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

  • NCT05000216COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

• Neuromuscular Diagnostic Center - Massachusetts General Hospital

  Boston, Massachusetts 02114

  3 trials

  • NCT06716931Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

    Contact: Blanca Escauriaza, RN

  • NCT06450886Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

  • NCT05721573A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

• Center for Addiction Medicine, Massachusetts General Hospital

  Boston, Massachusetts 02114

  2 trials

  • NCT07789132Evaluation of Community Health Worker Support to Help People With Serious Mental Illness to Quit Smoking

    Contact: Gladys Pachas, MD, MPH

  • NCT06584942Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

• Massachusetts General Hospital

  Lexington, Massachusetts 02421

  2 trials

  • NCT06042257Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

  • NCT04278404Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    Contact: Chi Hornik

• Massachusetts General Hospital

  Somerville, Massachusetts 02144

  2 trials

  • NCT07102797ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence

    Contact: Rachel Whooten

  • NCT05358353A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

• Massachusetts General Hospital/Dana Farber Cancer Institute

  Boston, Massachusetts 02114

  2 trials

  • NCT04981119Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Contact: Clinical Trials

  • NCT03435796Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

    Contact: Jeremy Abramson, Site 01012

• Massachusetts General Hospital-Hospital

  Boston, Massachusetts 02114

  2 trials

  • NCT07575269Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation

    Contact: Peter Fox

  • NCT05443594A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

• Massachusetts General Hospital - Neurology

  Boston, Massachusetts 02114

  2 trials

  • NCT06914128A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  • NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

• Massachusetts General Hospital, Neuromuscular Diagnostic Center

  Boston, Massachusetts 02114

  2 trials

  • NCT07226830Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

    Contact: Amanda Guidon, MD MPH

  • NCT07224386Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis

    Contact: Amanda Guidon

• Massachusetts General Hospital Site Number : 8400001

  Boston, Massachusetts 02114

  2 trials

  • NCT06665308Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

  • NCT05237284Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

• Massachusetts General Hospital Site Number : 8400002

  Boston, Massachusetts 02114

  2 trials

  • NCT04659603Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

  • NCT03284957Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

• Massachusetts General Hospital (The General Hospital Corp.)

  Boston, Massachusetts 02114

  2 trials

  • NCT07277309Promoting Recovery After Brain Injury Using Focused Ultrasound

    Contact: Michael Young, MD, MPhil

  • NCT06939348Ultrasound Stimulation for Patients in a Disorder of Consciousness

    Contact: Michael Young, MD

• Wellman Center for Photomedicine, Massachusetts General Hospital

  Boston, Massachusetts 02114

  2 trials

  • NCT06934928Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

  • NCT04730583Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

• Boston Children's/Joslin Diabetes Center/Massachusetts General Hospital

  Boston, Massachusetts 02215

  1 trial

  • NCT06525259DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

    Contact: Jackson Tu

• Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital

  Boston, Massachusetts 02114

  1 trial

  • NCT05767593Clinical Validation of Samsung Smartwatch

• Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital

  Boston, Massachusetts 02114

  1 trial

  • NCT01075672Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals

• Dana-Farber/Massachusetts General Hospital, Inc

  Boston, Massachusetts 02215

  1 trial

  • NCT07300150A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    Contact: Leon Pappas

• Diabetes Research Center, Massachusetts General Hospital

  Boston, Massachusetts 02114

  1 trial

  • NCT07688070Verapamil Effect in Cystic Fibrosis-related Dysglycemia

    Contact: Melissa Putman

• Disparities Research Unit, Massachusetts General Hospital

  Boston, Massachusetts 02114

  1 trial

  • NCT07091032Building Connections

    Contact: Margarita Alegria, Ph.D.

• Laboratory for Translational Neurorecovery, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital

  Boston, Massachusetts 02114

  1 trial

  • NCT06998485Substrates for Post-Stroke Arm Rehabilitation

    Contact: Caroline Lambert

• Massachusetts General Hospital

  Waltham, Massachusetts 02451

  1 trial

  • NCT04844606A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

    Contact: Jess Kaplan (principal investigator)

• Massachusetts General Hospital, 55 Fruit Street, Yawkey 6A

  Boston, Massachusetts 02114

  1 trial

  • NCT07838311Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

    Contact: Aaron R Quiggle, MD, MS

• Massachusetts General Hospital - ALS Site

  Boston, Massachusetts 02129

  1 trial

  • NCT05189106Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

• Massachusetts General Hospital - Cardiology

  Boston, Massachusetts 02114

  1 trial

  • NCT07625215A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

• Massachusetts General Hospital_Cary

  Boston, Massachusetts 02114

  1 trial

  • NCT05726227A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

• Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114

  Boston, Massachusetts 02114

  1 trial

  • NCT06765291Behavioral Intervention for Youth to Promote Vaping Cessation

    Contact: Julia Jashinski, MSW

• Massachusetts General Hospital - Center for Celiac Research and Treatment

  Boston, Massachusetts 02114

  1 trial

  • NCT04671433Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

• Massachusetts General Hospital - Clinical Genetic Facility

  Boston, Massachusetts 02114

  1 trial

  • NCT06435221Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

• Massachusetts General Hospital, Co-Enrolling through ABC-DS Only

  Boston, Massachusetts 02114

  1 trial

  • NCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)

    Contact: Herminia Herminia Diana Rosas (principal investigator)

• Massachusetts General Hospital - Crohn's and Colitis Center

  Boston, Massachusetts 02114

  1 trial

  • NCT02914535Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

• Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164257

  Boston, Massachusetts 02114

  1 trial

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• Massachusetts General Hospital - Dana Farber

  Boston, Massachusetts 02114

  1 trial

  • NCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

• Massachusetts General Hospital (Data Collection and Specimen Analysis)

  Boston, Massachusetts 02114

  1 trial

  • NCT03824483Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

• Massachusetts General Hospital, Healey & AMG Center for ALS

  Boston, Massachusetts 02114

  1 trial

  • NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

    Contact: Lucy Lee

• Massachusetts General Hospital /ID# 141552

  Boston, Massachusetts 02114

  1 trial

  • NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

• Massachusetts General Hospital /ID# 153990

  Boston, Massachusetts 02114

  1 trial

  • NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

• Massachusetts General Hospital /ID# 155267

  Boston, Massachusetts 02114

  1 trial

  • NCT02988960A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

• Massachusetts General Hospital /ID# 165678

  Boston, Massachusetts 02114

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Massachusetts General Hospital /ID# 200474

  Boston, Massachusetts 02114

  1 trial

  • NCT03569293Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

• Massachusetts General Hospital /ID# 200752

  Boston, Massachusetts 02114

  1 trial

  • NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

• Massachusetts General Hospital /ID# 203215

  Boston, Massachusetts 02114

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Massachusetts General Hospital /ID# 207549

  Boston, Massachusetts 02114

  1 trial

  • NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

• Massachusetts General Hospital /ID# 217307

  Boston, Massachusetts 02114

  1 trial

  • NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

• Massachusetts General Hospital /ID# 221559

  Boston, Massachusetts 02114

  1 trial

  • NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

• Massachusetts General Hospital /Id# 224335

  Boston, Massachusetts 02114

  1 trial

  • NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

• Massachusetts General Hospital /ID# 225068

  Boston, Massachusetts 02114

  1 trial

  • NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

• Massachusetts General Hospital /ID# 245233

  Boston, Massachusetts 02114

  1 trial

  • NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

• Massachusetts General Hospital /ID# 245239

  Boston, Massachusetts 02114

  1 trial

  • NCT05451810A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

• Massachusetts General Hospital /ID# 250142

  Boston, Massachusetts 02114

  1 trial

  • NCT05782907Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

• Massachusetts General Hospital /Id# 259817

  Boston, Massachusetts 02114

  1 trial

  • NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

• Massachusetts General Hospital /Id# 261051

  Boston, Massachusetts 02114

  1 trial

  • NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

• Massachusetts General Hospital /ID# 261093

  Boston, Massachusetts 02114

  1 trial

  • NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Massachusetts General Hospital /ID# 268879

  Boston, Massachusetts 02114

  1 trial

  • NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

• Massachusetts General Hospital /ID# 273608

  Boston, Massachusetts 02114

  1 trial

  • NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

• Massachusetts General Hospital /ID# 278119

  Boston, Massachusetts 02114

  1 trial

  • NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

• Massachusetts General Hospital - Main Campus

  Boston, Massachusetts 02114

  1 trial

  • NCT07629960A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    Contact: Blueprint Medicines

• Massachusetts General Hospital (MG)

  Boston, Massachusetts 02114

  1 trial

  • NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    Contact: Erasca Clinical Team Team

• Massachusetts General Hospital - Pediatric Epilepsy Program

  Boston, Massachusetts 02114

  1 trial

  • NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

• Massachusetts General Hospital - Pulmonary Associates

  Boston, Massachusetts 02114

  1 trial

  • NCT06097260Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

• Massachusetts General Hospital: Rheumatology

  Boston, Massachusetts 02114

  1 trial

  • NCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

    Contact: Sheila Arvikar, MD

• Massachusetts General Hospital (Site 0018)

  Boston, Massachusetts 02114

  1 trial

  • NCT05458297A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

• Massachusetts General Hospital (Site 0038)

  Boston, Massachusetts 02114

  1 trial

  • NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

• Massachusetts General Hospital (Site 0062)

  Boston, Massachusetts 02114

  1 trial

  • NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

• Massachusetts General Hospital (Site 0094)

  Boston, Massachusetts 02114

  1 trial

  • NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

• Massachusetts General Hospital (Site 0111)

  Boston, Massachusetts 02114

  1 trial

  • NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    Contact: Study Coordinator

• Massachusetts General Hospital (Site 0126)

  Boston, Massachusetts 02114

  1 trial

  • NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

• Massachusetts General Hospital (Site #0131)

  Boston, Massachusetts 02114

  1 trial

  • NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Contact: Principal Investigator

• Massachusetts General Hospital (Site 0136)

  Boston, Massachusetts 02114

  1 trial

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

• Massachusetts General Hospital (Site 0603)

  Boston, Massachusetts 02114

  1 trial

  • NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

• Massachusetts General Hospital (Site 1035)

  Boston, Massachusetts 02114

  1 trial

  • NCT04624243Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

• Massachusetts General Hospital (Site 1558)

  Boston, Massachusetts 02114

  1 trial

  • NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

• Massachusetts General Hospital (Site 1622)

  Boston, Massachusetts 02114

  1 trial

  • NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

• Massachusetts General Hospital (Site 1927)

  Boston, Massachusetts 02114

  1 trial

  • NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

• Massachusetts General Hospital (Site 3571)

  Boston, Massachusetts 02114

  1 trial

  • NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

• Massachusetts General Hospital (Site 4003)

  Boston, Massachusetts 02114

  1 trial

  • NCT05270668Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

• Massachusetts General Hospital Site Number: 8400004

  Boston, Massachusetts 02114

  1 trial

  • NCT07007962Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

• Massachusetts General Hospital- Site Number : 8400009

  Boston, Massachusetts 02114

  1 trial

  • NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

• ~Massachusetts General Hospital Site Number : 8400011

  Boston, Massachusetts 02114

  1 trial

  • NCT03754790Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

• ~Massachusetts General Hospital- Site Number : 8400017

  Boston, Massachusetts 02114

  1 trial

  • NCT05911763A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

• Massachusetts General Hospital Site Number : 840002

  Boston, Massachusetts 02114

  1 trial

  • NCT02201108Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

• Massachusetts General Hospital- Site Number : 8401192

  Boston, Massachusetts 02114

  1 trial

  • NCT06130566A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

• Massachusetts General Hospital Site Number : 84038

  Boston, Massachusetts 02114

  1 trial

  • NCT04562766Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

• Massachusetts General Hospital (Surgical)

  Boston, Massachusetts 02114

  1 trial

  • NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

• Massachusetts General Hospital, Translational and Clinical Research Center

  Boston, Massachusetts 02114

  1 trial

  • NCT04798079Systems Biology of Early Atopy

• Massachusetts General Hospital: Transplantation (Site #: 71107)

  Boston, Massachusetts 02114

  1 trial

  • NCT06056102CAR-T Cell Therapy for Desensitization in Kidney Transplantation

    Contact: Sydney Guthrie-Baker

• Massachusetts General Hospital, University of California San Francisco, University of Utah

  Boston, Massachusetts 02114

  1 trial

  • NCT05150093Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor

    Contact: Kristina Simonyan, MD, PhD

• Mass General / North Shore Can

  Boston, Massachusetts 02114

  1 trial

  • NCT03505320A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer